Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCommunity-Care Part D Formulary Coverage | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCommunity-CarePolicy N/A

    Senior Health Plan Part D Formulary (abridged) — Prescription Drug Coverage Criteria

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the plan's prescription drug formulary, coverage rules (prior authorization, step therapy, quantity limits), and cost-sharing for Senior Health Plan members (Medicare Advantage plans listed) and network pharmacy use.

    Policy Summary
    PayerCommunity-Care
    PolicySenior Health Plan Part D Formulary (abridged) — Prescription Drug Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date04/22/2026
    Last ReviewApr 22, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization and submit supporting documentation when a drug is marked PA, PA_NSO, PA_BvD or NDS PA to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    04/22/2026formulary last updated
    30 daysadvance notice for mid-year changes
    72/24 hrsexception decision timelines
    $0/$5/20%example retail copays
    multiplePA / QL presence
    Tier 1-5+Specformulary tiers

    Formulary Coverage Rules

    General coverage conditions

    Covered when ALL of the following are met:

    General coverage: Drug is listed on the plan formulary AND the prescription is filled at a plan network pharmacy AND the drug is medically necessary per plan rules.

    See Evidence of Coverage for details.

    Temporary supply and exception handling

    Temporary and exception coverage provided in specific situations:

    Temporary supply / transition exceptions: For each drug not on the formulary or with a coverage restriction, plan may provide a temporary supply while member/prescriber pursues an exception or alternative therapy.30 days / 31 days

    New or continuing members: up to a 30‑day temporary supply; long‑term care residents may receive a 31‑day emergency supply; temporary supply during setting‑of‑care changes also available.

    Policy Summary
    PayerCommunity-Care
    PolicySenior Health Plan Part D Formulary (abridged) — Prescription Drug Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date04/22/2026
    Last ReviewApr 22, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization and submit supporting documentation when a drug is marked PA, PA_NSO, PA_BvD or NDS PA to avoid claim denial.
    SourceLink
    On This Page
    Formulary Coverage RulesFormulary Line Coding & FlagsPrior Authorization, Step Therapy, and DocumentationFormulary Flags and LegendInitial Coverage & Step ExamplesPer-Product Quantity Limits (Selected Examples)Document Context
    Exception request process: Member or prescriber requests a formulary exception with supporting medical statement explaining why formulary alternative or restriction would not be as effective or would cause harm.Decision timelines: 72 / 24 hours

    Standard decision within 72 hours; expedited decision within 24 hours when clinically necessary.

    Effect of not obtaining prior authorization: If required prior authorization is not obtained, the plan may deny coverage for the drug.

    Prescribers should follow PA procedures in the formulary listing.

    Formulary inclusion with tiering and restrictions

    Drugs listed on the Part D formulary are included with an assigned tier and, where shown, may have requirement/limit annotations:

    Formulary inclusion: Each listed drug entry includes a drug tier and may include one or more Requirement/Limits annotations such as PA, PA_BvD, PA_NSO, NDS PA, ST_NSO, and QL.

    Examples from table: REPATHA (PA QL=2 ML/28 Days); ondansetron oral solution (PA_BvD QL=900 ML/30 Days); dapagliflozin (QL=30 EA/30 Days).

    Formulary line-item coverage

    Per‑line coverage and constraints apply to each strength/formulation listed:

    Per‑entry coverage info: Each formulary line item is governed by its DRUG TIER and any displayed Requirements/Limits codes (e.g., PA_NSO, NDS, QL). Coverage for that exact strength/formulation follows the listed controls.

    Examples: PA_NSO flags for antipsychotics and PA_NSO/NDS rules for injectables with mL‑based QLs; see table lines for specific QL/NDS values.

    Formulary coverage (table-based)

    Formulary coverage and dispensing limits — drugs are covered subject to tier placement and the Requirements/Limits shown in the table:

    Table-based coverage conditions: Coverage for a listed product requires adherence to the drug tier placement and any Requirements/Limits shown (quantity limits, prior authorization, non‑standard dispensing).

    Quantity limits (QL) are expressed as units per period (e.g., QL=30 EA/30 Days) and numeric dose supply (NDS) values are used for injectables (e.g., NDS QL=.75 ML/28 Days).

    Formulary coverage with utilization controls

    Coverage follows the formulary listing and the utilization controls shown for each product:

    Formulary coverage with utilization controls: A drug listed on the formulary is covered subject to its tier and any listed utilization controls such as prior authorization (PA, PA_NSO, NDS PA), step therapy (ST_NSO), and quantity limits (QL).

    Prescribers should obtain PA where indicated and ensure dispensed quantity complies with the listed QL/NDS to avoid claim denial or adjustment.

    The formulary may be changed when a drug is withdrawn from the market. Per the formulary: when a drug is withdrawn from sale by the manufacturer or the FDA determines it should be withdrawn for safety or effectiveness reasons, the plan may immediately remove the drug from the formulary and it will not be covered. The plan will later provide notice to affected members and describe exception rights and transition options.

    This excerpt is an abridged segment of the full Part D formulary. It does not reproduce the complete legend or the start-of-table explanations that define the abbreviations and symbols used in the Requirements/Limits column. For definitions of flags such as PA, PA_NSO, NDS, QL and other table abbreviations, refer to the beginning of the full formulary table and the formulary legend.

    Within these chunks there are no standalone plan-level exclusions listed. Many line items show only drug, strength/form, tier and, where applicable, Requirements/Limits; entries that do not include a Requirements/Limits value appear here without additional restrictions and therefore are not shown as excluded in this excerpt.

    This excerpt of the formulary does not identify any drugs as explicitly excluded from coverage. The pages shown are a listing of formulary lines and, where present, their Requirements/Limits; explicit exclusions are not present in these chunks.

    The segment provided is a formulary listing of topical antibiotic products and related entries and does not contain explicit medical-exclusion conditions. It lists drug line items and tiers rather than medical exclusion criteria.

    Some drugs listed on the formulary require prior authorization. The formulary warns that if prior authorization is required and is not obtained, the plan may not cover the drug. When a Requirements/Limits field contains PA, PA_NSO, PA_BvD, NDS PA or similar flags, prescribers must submit the required prior authorization and supporting documentation per the plan’s processes.

    This excerpt does not include any explicit statements declaring products or uses as 'not medically necessary.' The document directs readers to the full formulary legend and related sections for complete coverage determinations.

    The pages in this extract do not contain explicit 'not medically necessary' determinations. The content here is a formulary table showing drug names, tiers and, where applicable, Requirements/Limits; clinical medical-necessity findings are not stated in these chunks.

    No explicit 'not medically necessary' language appears in this segment. The lines shown list propranolol and related agents by strength and tier with blank Requirements/Limits fields where no additional restrictions are recorded in this excerpt.

    Formulary Line Coding & Flags

    Formulary entries (examples)mixed
    ATROVENT 17MCG HFA INHALERREQUIREMENTS/LIMITS = QL=25.80 GM/30 Days
    INCRUSE ELLIPTA 62.5MCG/INH POWDER INHALERDRUG TIER = 3; REQUIREMENTS/LIMITS = QL=30 EA/30 Days
    ipratropium bromide 0.02% inh solnDRUG TIER = 2; REQUIREMENTS/LIMITS = PA_BvD
    SPIRIVA RESPIMAT 1.25MCG/ACT INHALERDRUG TIER = 3; REQUIREMENTS/LIMITS = QL=4 GM/30 Days
    montelukast 10mg tabDRUG TIER = 1; REQUIREMENTS/LIMITS = .
    Anticoagulant QLsmixed
    QL=60 EA/30 Dayscommon anticoagulant quantity limit (examples: dabigatran, rivaroxaban)
    QL=620 ML/30 Daysrivaroxaban 1mg/ml oral suspension quantity limit
    Anticonvulsant annotationsmixed
    PA_NSOprior authorization notation applied to certain anticonvulsant products (e.g., brivaracetam)
    NDSnotation appearing with DIACOMIT indicating specialty distribution/refill rules
    Formulary annotations and quantity-limit codesmixed
    QL=30 EA/30 Daysquantity limit example (e.g., dapagliflozin, FARXIGA, JARDIANCE)
    PA_BvDprior authorization with business validation (appears for ondansetron and related entries)
    NDS PAnon-standard distribution / specialty prior authorization (appears for CRESEMBA)
    QL=900 ML/30 Daysquantity limit for ondansetron 0.8mg/ml oral solution
    QL=2 ML/28 Daysquantity limit example for REPATHA 140MG/ML
    QL=84 EA/28 Daysquantity limit for XERMELO 250MG TAB
    Listed drugs and formulations (excerpt)NDC|proprietary names
    NOVOLIN MIX (70/30) 100UNIT/ML FLEXPEN (3ML)listed product and form; REQUIREMENTS/LIMITS = INS
    TOUJEO 300UNIT/ML PEN INJ (1.5ML)listed product and form; REQUIREMENTS/LIMITS = INS
    TRESIBA 100UNIT/ML PEN INJ (3ML)listed product and form; REQUIREMENTS/LIMITS = INS
    DAPAGLIFLOZIN 10MG TABlisted product and form; REQUIREMENTS/LIMITS = QL=30 EA/30 Days
    REPATHA 140MG/ML AUTO-INJECTORlisted product and form; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days
    CRESEMBA 186MG CAPlisted product and form; REQUIREMENTS/LIMITS = NDS PA
    Formulary flags and limit codesmixed
    PA_NSOPrior authorization / non-standard override flag as shown in table
    QLQuantity limit (units per period) as shown in Requirements/Limits
    EAEach (unit) used in quantity limit expressions
    Formulary drug entries and their listed detailsmixed
    TAFINLAR 10MG TABTAFINLAR 10MG TAB FOR ORAL SUSP, REQUIREMENTS/LIMITS = NDS PA_NSO QL=120 EA/30 Days = NDS PA_NSO QL=840 EA/28 Days
    TAFINLAR 50MG CAPREQUIREMENTS/LIMITS = NDS PA_NSO QL=120 EA/30 Days
    TAFINLAR 75MG CAPREQUIREMENTS/LIMITS = NDS PA_NSO QL=120 EA/30 Days
    TALZENNA 0.1MG CAPREQUIREMENTS/LIMITS = NDS PA_NSO QL=120 EA/30 Days = NDS PA_NSO QL=30 EA/30 Days
    TAZVERIK 200MG TABDRUG TIER = 5; REQUIREMENTS/LIMITS = NDS PA_NSO QL=240 EA/30 Days
    TEPMETKO 225MG TABDRUG TIER = 5; REQUIREMENTS/LIMITS = NDS PA_NSO QL=60 EA/30 Days
    TIBSOVO 250MG TABDRUG TIER = 5; REQUIREMENTS/LIMITS = NDS PA_NSO QL=60 EA/30 Days
    TRUQAP 200MG TABDRUG TIER = 5; REQUIREMENTS/LIMITS = NDS PA_NSO QL=64 EA/28 Days
    TURALIO 125MG CAPDRUG TIER = 5; REQUIREMENTS/LIMITS = NDS PA_NSO QL=120 EA/30 Days
    VITRAKVI 20MG/ML ORAL SOLNDRUG TIER = 5; REQUIREMENTS/LIMITS = NDS PA_NSO QL=300 ML/30 Days
    1–10 of 25
    1/3
    Quantity and supply codesmixed
    QL=30 EA/30 DaysQuantity limit: 30 each per 30 days
    QL=60 EA/30 DaysQuantity limit: 60 each per 30 days
    QL=240 ML/30 DaysQuantity limit: 240 mL per 30 days (oral solution example)
    NDS QL=.75 ML/28 DaysNumeric dose supply limit: 0.75 mL per 28 days (INVEGA SUSTENNA example)
    NDS QL=1 ML/28 DaysNumeric dose supply limit: 1 mL per 28 days
    NDS QL=1.50 ML/28 DaysNumeric dose supply limit: 1.50 mL per 28 days
    NDS QL=.25 ML/28 DaysNumeric dose supply limit: 0.25 mL per 28 days
    Drug tier assignmentsmixed
    DRUG TIER = 1Tier 1 preferred generic / lower cost sharing
    DRUG TIER = 2Tier 2
    DRUG TIER = 4Tier 4
    DRUG TIER = 5Tier 5 (specialty / high cost)
    Quantity limits and prior authorization codes extractedmixed
    QL=240 EA/30 Daysquantity limit example for ENTRESTO oral pellets
    PA QL=90 EA/30 Daysdroxidopa 100mg cap prior authorization and quantity limit
    PA QL=180 EA/30 Daysdroxidopa 200mg and 300mg caps prior authorization and quantity limit
    PA QL=60 EA/30 Daysivabradine strengths prior authorization and quantity limit
    QL=60 EA/30 Daysranolazine formulations quantity limit
    PA QL=30 EA/30 DaysVERQUVO strengths prior authorization and quantity limit
    NDS PA QL=240 ML/30 DaysEVRYSDI oral solution non-standard dose prior auth and quantity limit
    NDS PA QL=30 EA/30 DaysEVRYSDI tablet NDS prior auth and quantity limit
    NDS PA QL=70 ML/28 DaysRADICAVA oral suspension NDS prior auth and quantity limit
    QL=60 EA/30 Dayssacubitril/valsartan strengths quantity limit
    1–10 of 11
    1/2
    Selected quantity limits (examples)
    Example QL formatQL=30 EA/30 Days (e.g., dapagliflozin 10mg tab, ezetimibe/simvastatin entries)
    High inhaler/metric QLQL=25.80 GM/30 Days (ATROVENT 17MCG HFA)
    Large-volume oral solution QLQL=1800 ML/30 Days (methylphenidate 1mg/ml oral soln)
    Per-prescription tablet example30 tablets per prescription (simvastatin 80mg example in quantity limits)
    Short-interval QL exampleQL=280 ML/28 Days (tobramycin 300mg/5ml inhalation solution)
    Inhaler per-month unit limit
    Typical inhaler monthly unit limitQL=60 EA/30 Days (common per powder inhaler entries, e.g., wixela, INCRUSE equivalents)
    Alternate inhaler metric entriesQL=120 ML/30 Days = QL=60 EA/30 Days (TRELEGY ELLIPTA shown as PA_BvD QL=120 ML/30 Days = QL=60 EA/30 Days)
    Smaller-dose inhaler metricQL=36 GM/30 Days (VENTOLIN 108MCG HFA example)
    Quantity limits examples (higher-volume)
    High-count tablet QL exampleQL=360 EA/30 Days (DIACOMIT 250mg cap and powder for oral suspension)
    Large oral solution QL exampleQL=600 ML/30 Days (EPIDIOLEX 100mg/mL oral solution)
    Large suspension QL exampleQL=720 ML/30 Days (perampanel suspension example range)
    Mid-range tablet QL exampleQL=240 EA/30 Days (diclofenac sodium 25mg DR tab example)
    Quantity limits examples (assorted)
    Common 30-per-month QLQL=30 EA/30 Days (appears throughout for many oral tablets such as dapagliflozin, ezetimibe/simvastatin)
    Small mL injectable/pen QLQL=2 ML/28 Days (REPATHA 140mg/mL auto-injector/syringe)
    Very large solution QLQL=1200 ML/30 Days (RALDESY 10mg/mL oral solution example)
    Large oral solution exampleQL=900 ML/30 Days (ondansetron 0.8mg/mL oral solution)
    Sample quantity limits (oncology/high‑volume examples)
    Oncology high and varied QLsExamples range from QL=3 EA/28 Days (NINLARO capsules) up to QL=840 EA/28 Days (TAFINLAR 10mg tab for oral suspension)
    Common oncology tablet QLQL=120 EA/30 Days (TAFINLAR 10mg tab alternate entry)
    Mid-range oncology QLQL=240 EA/30 Days (TAZVERIK 200mg tab)
    Pack/titration QLsQL=112 EA/28 Days (COMETRIQ cap 140mg daily dose pack)
    Examples of quantity limits (additional)
    Additional common QLsQL=240 EA/30 Days (TAZVERIK 200mg tab shown)
    Large oral solution QLQL=300 ML/30 Days (VITRAKVI 20mg/mL oral solution)
    Standard tablet QLQL=60 EA/30 Days (many specialty oral caps/tabs such as XALKORI 200mg cap shown)
    NDS quantity limits for injectables (examples)
    NDS injectable small-volume QLsNDS QL=0.75 ML/28 Days; NDS QL=1 ML/28 Days; NDS QL=1.50 ML/28 Days (e.g., INVEGA SUSTENNA injectable numeric dose supply limits)
    NDS per‑syringe QL mappingExamples map PA_NSO QL=30 EA/30 Days to NDS QL values in mL per 28 days depending on syringe strength
    Small mL per period examplesQL=.25 ML/28 Days shown for lower-strength syringes

    Prior Authorization, Step Therapy, and Documentation

    Prior Authorization

    Obtain prior authorization per PA/PA_NSO/PA_BvD flags

    Prescribers must obtain prior authorization when the formulary lists PA, PA_NSO, or PA_BvD for a product; PA_NSO applies to new starts and PA_BvD is used when a Part B vs Part D determination is required. Follow the plan's prior authorization pathways (including non-standard/NDS routes) before dispensing.

    • PA_NSO = prior authorization restriction for new starts only
    • PA_BvD = prior authorization to determine Part B vs Part D payment responsibility
    • NDS PA indicates non-standard distribution with PA requirements
    Prior Authorization

    PA required for many specialty/high-cost agents

    Numerous specialty and high-cost agents are marked NDS PA or PA in the Requirements/Limits and require prescribers to submit prior authorization before the plan will cover them.

    • Examples: OLUMIANT, RINVOQ, XELJANZ, and anti‑TNF agents are listed with NDS PA QL entries
    Prior Authorization

    PA plus quantity limits for stimulants/wakefulness agents

    Selected stimulants and wakefulness agents show both prior authorization (PA) and quantity limits (QL); prescribers must request PA and ensure prescriptions conform to the listed QL.

    • Examples: atomoxetine entries include QL values; methylphenidate oral solutions list QL=1800 ML/30 Days
    Prior Authorization

    PA required for annotated inhaled and anticonvulsant products

    Several inhaled and anticonvulsant products are annotated with PA_BvD or PA_NSO in the Requirements/Limits; prescribers must obtain the indicated prior authorization before coverage.

    • Examples: ipratropium inhalation solution marked PA_BvD; multiple anticonvulsants (brivaracetam, DIACOMIT, EPIDIOLEX) show PA_NSO/NDS PA_NSO
    Prior Authorization

    PA required for formulary entries flagged PA_NSO / NDS PA_NSO

    Drugs flagged with PA_NSO or NDS PA_NSO in the Requirements/Limits require prior authorization or non-standard review; prescribers must secure authorization and observe any quantity constraints.

    • PA_NSO and NDS PA_NSO appear across many line items and trigger PA requirements
    Prior Authorization

    Submit PA for listed products with PA or specialty PA flags

    Many listed drugs include PA or specialty PA flags in their Requirements/Limits; providers must submit prior authorization per the plan when those flags are present.

    • Examples in the table include EXXUA formulations (PA_NSO), RALDESY (PA_NSO QL), and several GLP‑1/insulin products showing PA/QL
    Prior Authorization

    PA (and QL) required for select specialty/high‑cost drugs

    Select specialty/high‑cost drugs are listed with PA and QL entries; prescribers must obtain prior authorization and adhere to the quantity limits shown for coverage.

    • Example: REPATHA requires PA with QL=2 ML/28 Days; CRESEMBA is listed as NDS PA
    Prior Authorization

    Obtain PA when PA_NSO is listed

    Numerous agents in the antineoplastic and other specialty sections are marked PA_NSO; prescribers must obtain prior authorization when PA_NSO appears in Requirements/Limits and provide supporting documentation.

    • PA_NSO appears on many oncology/specialty entries and often is paired with NDS or QL values
    Prior Authorization

    PA required for entries marked NDS PA_NSO or PA_NSO

    Several drugs are listed with 'NDS PA_NSO' or 'PA_NSO' indicating prior authorization or non‑standard prior authorization is required prior to coverage; prescribers must secure authorization before dispensing.

    • NDS PA_NSO entries include numeric dose‑supply quantity limits for injectables and specialty items
    Prior Authorization

    PA required for PA_NSO‑listed psychotropic agents

    Multiple psychotropic agents include PA_NSO in their Requirements/Limits; prescribers should submit prior authorization for these drugs before the plan will cover them.

    • Examples: NUPLAZID, VRAYLAR, and long‑acting injectable antipsychotics show PA_NSO QL entries
    Prior Authorization

    PA required for select high‑cost antivirals (NDS PA)

    High‑cost antiviral and hepatitis C direct‑acting agents are listed with NDS PA or PA flags; prescribers must obtain prior authorization before coverage and comply with the listed quantity limits.

    • Examples: MAVYRET and SOFOSBUVIR/VELPATASVIR are listed with NDS PA QL values
    Prior Authorization

    PA required for select listed drugs with PA/QL

    Certain listed drugs (e.g., droxidopa, ivabradine, VERQUVO, EVRYSDI, RADICAVA) have PA and QL annotations; prescribers must request prior authorization and ensure prescriptions meet the quantity limits shown.

    • Example: droxidopa 100 mg cap = PA QL=90 EA/30 Days; EVRYSDI oral solution = NDS PA QL=240 ML/30 Days
    Prior Authorization

    PA required for flagged topical and related agents

    Topical and other products marked 'PA' or 'NDS PA' in Requirements/Limits require prior authorization before coverage; prescribers must submit PA to avoid denial.

    • Examples: multiple tretinoin formulations show PA QL=45 GM/30 Days; OTEZLA and SKYRIZI are listed with NDS PA/PA and QL values
    Step Therapy

    Follow step therapy (ST / ST_NSO) when flagged

    Step therapy may apply when ST or ST_NSO appears; ST_NSO indicates step edits apply to new starts only — prescribers should follow the plan's step sequence where specified.

    • ST_NSO = step therapy for new starts only; TRINTELLIX entries show ST_NSO QL=30 EA/30 Days
    Note

    No explicit step‑therapy sequences in this excerpt — consult full guidance

    The formulary excerpt includes category‑level Requirements/Limits for some classes but does not provide explicit step‑therapy sequences in this segment; prescribers should consult the plan's full PA/ST guidance when a step edit is indicated.

    • Category‑level flags are present (e.g., ADHD class), but explicit prior step drugs or sequences are not listed here
    Step Therapy

    Step/UM indicators present (e.g., TRINTELLIX ST_NSO)

    Some tiered products (for example TRINTELLIX) include ST_NSO indicating that step therapy or utilization management may apply; prescribers must meet step criteria where required.

    • TRINTELLIX 5/10/20 mg tabs list ST_NSO QL=30 EA/30 Days
    Step Therapy

    TRINTELLIX requires ST_NSO for new starts

    TRINTELLIX products are assigned ST_NSO in Requirements/Limits, meaning step edits for new starts must be satisfied per plan rules before coverage.

    • TRINTELLIX 5/10/20 mg tabs — ST_NSO QL=30 EA/30 Days
    Note

    No explicit step sequences shown — follow full plan step/ST guidance

    This formulary excerpt does not list explicit multi‑step sequences; when step therapy is required the prescriber must follow the plan's documented step requirements found in the full formulary or PA guidance.

    • Plan-level step sequences and prior authorization criteria are published in detailed PA/ST documents referenced in the formulary
    Prior Authorization

    Hepatitis C antivirals flagged for utilization management (NDS PA)

    Hepatitis C DAAs and other specialty antivirals are flagged NDS PA, indicating utilization management applies; prescribers must obtain PA though specific step sequences are not shown here.

    • Examples include SOFOSBUVIR/VELPATASVIR and VOSEVI listed with NDS PA QL values
    Documentation Required

    Provide a medical statement for formulary exception requests (72 / 24 hr timelines)

    When requesting a formulary exception, the prescriber must provide a supporting medical statement explaining the medical necessity; standard decision timelines are 72 hours and expedited decisions 24 hours upon receipt of the prescriber's statement.

    • Prescriber must state medical reasons supporting the exception
    • Decision timelines: standard 72 hours; expedited 24 hours
    Documentation Required

    Submit clinical context for PA_BvD (Part B vs Part D) determinations

    For drugs annotated PA_BvD, prescribers should submit clinical information describing the drug's use and setting to allow the plan to determine whether Medicare Part B or Part D is the payment responsibility.

    • PA_BvD = prior authorization to determine Part B vs Part D coverage
    Billing Rule

    Ensure dispensing complies with listed quantity limits (QL)

    Quantity limits (QL) are specified per product (e.g., QL=30 EA/30 Days); prescribers and pharmacists must ensure prescriptions do not exceed the listed QL unless prior authorization or an approved exception is obtained.

    • Examples: DAPAGLIFLOZIN 10MG TAB = QL=30 EA/30 Days; methylphenidate oral solutions list ML QLs
    Documentation Required

    Provide medical necessity documentation for PA_NSO / NDS PA_NSO drugs

    When a formulary line shows PA_NSO or NDS PA_NSO, providers must supply documentation supporting medical necessity and demonstrate adherence to the listed quantity limits as part of the prior authorization submission.

    • PA_NSO/NDS PA_NSO entries commonly require medical necessity documentation with PA submission
    Documentation Required

    Document PA and ML for injectable GLP‑1 agents (MOUNJARO, OZEMPIC, TRULICITY)

    Injectable GLP‑1 agents and pen products in the formulary list PA and ML/QL requirements; prescribers must include documentation consistent with prior authorization rules when requesting coverage.

    • Examples: MOUNJARO entries show PA QL=2 ML/28 Days; OZEMPIC entries show PA QL=3 ML/28 Days; TRULICITY entries show PA QL=2 ML/28 Days
    Billing Rule

    Match prescription/claim data to formulary line‑item (name, strength, tier, Requirements/Limits)

    Formulary entries use annotations such as PA_BvD, PA, NDS PA, PA_NSO, ST_NSO and QL per strength/formulation; ensure prescription and claim data match the listed name, strength/formulation, tier, and Requirements/Limits when submitting a PA or claim.

    • Provide exact drug name, strength/form, intended days' supply, and any clinical justification requested
    Documentation Required

    Ensure prescription matches formulary strength/form and PA_NSO/QL codes

    Pharmacies must present a prescription that matches the listed strength and formulation and adhere to PA_NSO and quantity‑limit codes shown in the formulary; dispensing beyond QL or without PA may lead to claim adjustments or denials.

    • Pharmacy should confirm QL (EA/30 Days, ML/28 Days, etc.) and PA flags prior to dispensing
    Billing Rule

    Adhere to table QL periods and units when dispensing

    Follow the exact quantity limits shown in the table for dispensing (examples include EA/30 Days, EA/28 Days, ML/30 Days); prescriptions exceeding these limits require justification or prior authorization.

    • Examples: REPATHA QL=2 ML/28 Days; many injectables list NDS mL limits per 28 days
    Billing Rule

    Conform to NDS (mL) quantity limits for injectables

    Long‑acting injectables and NDS items show numeric dose supply (mL) limits (e.g., .75 mL/28 Days, 1 mL/28 Days); prescribers and pharmacies must conform dispensing and PA requests to these NDS QL values.

    • INVEGA SUSTENNA examples show NDS QL values (e.g., .25 mL/28 Days, .50 mL/28 Days, 1.50 mL/28 Days)
    Documentation Required

    Include exact formulary details on PA/claim submissions

    When submitting PA or claims, include drug name, strength/formulation, tier, and Requirements/Limits (QL/PA flags) so the plan can match the request to the formulary entry and avoid processing delays.

    • Provide intended days' supply and quantity to align with QL values
    Documentation Required

    Provide PA documentation when table shows PA or QL

    If a formulary table line indicates PA and/or QL, prescribers should provide the required prior authorization documentation to the Part D PA process to support coverage.

    • PA and QL annotations on entries (e.g., droxidopa PA QL=90 EA/30 Days) require PA documentation
    Documentation Required

    Justify or obtain PA for prescriptions exceeding QL

    Prescriptions exceeding listed quantity limits per the specified period (QL=...) may require clinical justification or prior authorization before the plan will cover the excess amount.

    • Providers should document the medical necessity for quantities above the listed QL when requesting overrides
    Denial Risk

    Risk of denial if required PA is not obtained

    Failure to obtain required prior authorization where indicated may result in the plan denying coverage for the drug at the point of sale.

    • The formulary warns that lack of PA may lead to non‑coverage
    Denial Risk

    Denial risk for NDS/PA‑flagged drugs without PA

    Drugs flagged with 'NDS PA' or general 'PA' entries indicate claims may be denied without prior authorization or required documentation; prescribers must secure PA to avoid claim denial.

    • High‑cost and non‑standard distribution items commonly carry this denial risk
    Denial Risk

    PA required for some stimulants/wakefulness agents — denial risk if not obtained

    Selected stimulants and wakefulness agents include 'PA' in their Requirements/Limits, so prescribers must obtain prior authorization for these agents to prevent claim denial.

    • Examples include atomoxetine and methylphenidate formulations with QL and PA annotations
    Denial Risk

    Claims may be denied for PA_BvD / PA_NSO items without PA

    Products marked PA_BvD or PA_NSO require prior authorization per the formulary; claims submitted without the required PA may be denied or require manual review.

    • PA_BvD entries (e.g., ondansetron oral solution) and PA_NSO entries (multiple line items) trigger PA pathways
    Denial Risk

    PA_NSO / NDS PA_NSO drugs carry denial risk if requirements unmet

    Claims for drugs flagged with PA_NSO or NDS PA_NSO may be denied or require non‑standard review when quantity limits are exceeded or criteria are not met; prescribers should secure PA and document necessity.

    • Examples: DIACOMIT and EPIDIOLEX entries show NDS PA_NSO flags with QL values
    Denial Risk

    PA/QL/ST flags can trigger coverage denial if not met

    Coverage may be denied or limited if PA or QL specified for a product (PA_NSO, PA, ST_NSO, NDS PA) are not satisfied per the formulary listing; prescribers must follow these controls to obtain coverage.

    • Formulary flags indicate PA/QL/ST controls that determine coverage
    Denial Risk

    PA/QL/NDS flags trigger coverage controls

    Drugs marked with PA, PA_BvD, NDS, or QL may trigger coverage limits or prior authorization requirements per the formulary; prescribers should verify and comply with the listed controls.

    • Examples: REPATHA (PA QL), CRESEMBA (NDS PA) — coverage tied to listed requirements
    Denial Risk

    Denial risk when formulary requirements/QL not met

    Claims for listed drugs may be denied or require review if prescribers or pharmacies do not meet the listed requirements (e.g., PA_NSO) or exceed specified quantity limits; obtain PA and document as required.

    • Ensure PA submissions reference the formulary line's Requirements/Limits to avoid denials
    Prior Authorization

    PA_NSO entries require prior authorization — risk of denial if not obtained

    When a formulary entry shows 'PA_NSO' or 'NDS PA_NSO', prior authorization is indicated; prescribers must request PA for these items to prevent claim denial at point of sale.

    • PA_NSO commonly appears across specialty and oncology entries
    Prior Authorization

    Submit PA for PA_NSO‑listed drugs with clinical support

    PA_NSO‑listed drugs are subject to prior authorization review; prescribers should submit PA requests with supporting clinical information to secure coverage.

    • Examples include NUPLAZID and many VRAYLAR strengths showing PA_NSO QL=30 EA/30 Days
    Prior Authorization

    Obtain PA for select high‑cost antiviral agents (NDS PA indicated)

    Certain high‑cost agents (e.g., MAVYRET, SOFOSBUVIR/VELPATASVIR, VOSEVI, LIVTENCITY, PREVYMIS) list NDS PA or similar flags; prescribers must obtain PA to satisfy non‑standard distribution requirements before coverage.

    • NDS PA entries include specific QL values that must be followed
    Denial Risk

    Exceeding QL or lacking PA may trigger denial for listed products

    Claims exceeding specified quantity limits or lacking required prior authorization for products such as droxidopa, ENTRESTO oral pellets, ivabradine, VERQUVO, EVRYSDI, and RADICAVA may be denied; prescribers must secure PA or justification.

    • Examples: droxidopa PA QL=90/180 EA/30 Days; EVRYSDI NDS PA QL=240 ML/30 Days; RADICAVA NDS PA QL=70 ML/28 Days
    Prior Authorization

    PA required for flagged topical agents — obtain PA to avoid denial

    Topical agents flagged with 'PA' or 'NDS PA_NSO' require prior authorization or non‑standard dispensing authorization before coverage; prescribers should request PA to avoid denials.

    • Examples: multiple tretinoin formulations show PA QL=45 GM/30 Days; lidocaine topical entries show PA QL values
    Prior Authorization

    NDS PA required for select specialty agents (OTEZLA, SKYRIZI) — secure PA

    Entries showing 'NDS PA' for specialty agents such as OTEZLA and SKYRIZI indicate non‑standard distribution and prior authorization requirements; prescribers must obtain NDS/PA to ensure coverage.

    • OTEZLA entries list NDS PA QL values (e.g., QL=60 EA/30 Days); SKYRIZI lists PA QL=7 ML/365 Days

    Formulary Flags and Legend

    Formulary / Biological products and biosimilars
    Formulary / Drug List definitionFormulary (Drug List): list of covered drugs selected by the plan; biological products and biosimilars are included with substitution rules per state law.
    Biosimilars substitution noteSome biosimilars are interchangeable and may be substituted for original biological products at the pharmacy depending on state law.
    Location of full legend and abbreviationsAbbreviation legend referenced at the beginning of the full formulary table (see formulary start on page 10).
    QL = Quantity Limit (definition)
    Definition — QL (Quantity Limit)QL = Quantity limit (maximum quantity allowed per specified time period, e.g., QL=30 EA/30 Days)
    Examples of units used in QLEA = Each (unit); ML = milliliters; GM = grams
    Purpose of QLQL entries limit covered amount per prefill/daily/monthly/yearly period as shown in the Requirements/Limits column.
    PA_BvD / PA_NSO definitions
    PA_BvD definitionPA_BvD = Prior Authorization for Part B vs Part D Determination; prior authorization required to determine Part D coverage before dispensing.
    PA_NSO definitionPA_NSO = Prior Authorization Restriction for New Starts Only; PA required if drug is new to the member.
    Where usedThese flags appear in the Requirements/Limits column to indicate plan-specific PA pathways.
    PA_NSO / NDS PA_NSO flags
    PA_NSO flag meaningPA_NSO indicates prior authorization required for new starts only; without PA the plan may not cover the drug.
    NDS PA_NSO meaningNDS PA_NSO indicates non-extended day supply plus a PA restriction for new starts on specialty/limited-supply products.
    Clinical effectWhen PA_NSO or NDS PA_NSO appears, providers must submit required documentation per the formulary to obtain authorization.
    QL example notation (explain QL=## EA/## Days)
    QL notation explainedQL=360 EA/30 Days means a maximum of 360 each (tablets/capsules) covered per 30 days.
    QL with unitsNotation uses unit then period (e.g., EA for each, ML for milliliters, GM for grams) followed by /## Days.
    Examples in tableShown across formulary entries; follow the exact QL string on the Requirements/Limits column for dispensing rules.
    PA / step / flags (legend)
    PA and related flags listCommon flags: PA_NSO (prior auth for new starts), PA (prior authorization), ST_NSO (step therapy for new starts), NDS PA (non-extended day supply + PA), PA_BvD (Part B vs D PA).
    Where appliedFlags appear in Requirements/Limits to indicate utilization management requirements for the listed drug/formulation.
    Action requiredProviders must obtain the specified authorization or meet step criteria before coverage where these flags appear.
    Prior authorization with business validation (PA_BvD)
    PA_BvD meaningPA_BvD = prior authorization to determine Part B vs Part D coverage; required before dispensing when shown.
    ImplicationIf PA_BvD is present, prescriber must submit information to establish Part D payment prior to filling.
    Example in tableondansetron oral solution is listed with PA_BvD and a QL (PA_BvD QL=900 ML/30 Days).
    Quantity limit notation definition
    Quantity limit notationNotation format: QL=## UNIT/## Days (e.g., QL=30 EA/30 Days)
    Units usedEA (each), ML (milliliters), GM (grams), EA/28 Days or EA/30 Days depending on product packaging)
    Follow table for dispensingDispense and claims should match the QL period and unit shown to avoid denials or adjustments.
    NDS PA definition
    NDS PA definitionNDS PA = Non-Extended Day Supply with Prior Authorization; indicates the drug is limited to 1-month supply and requires PA for specialty distribution.
    Effect on supplyDrugs marked NDS are limited to 1-month supply for Retail and Mail Order unless otherwise specified.
    When usedApplied to specialty injectables, oral suspensions, and certain high-cost agents in the formulary.
    Table abbreviations (legend reference)
    Table abbreviations legendAbbreviations used in Requirements/Limits (e.g., PA, PA_NSO, NDS, QL, EA) are defined at the beginning of the formulary table.
    Where to find full legendSee the start of the formulary (page 10) for the complete legend and symbol definitions.
    Common abbreviationsExamples: PA = Prior Authorization; QL = Quantity Limit; ST = Step Therapy; NDS = Non-Extended Day Supply.
    PA_NSO / NDS PA_NSO (formulary flags)
    PA_NSO usage in formularyPA_NSO = prior authorization required for new starts; appears throughout Requirements/Limits to flag authorization need.
    NDS PA_NSO combined flagNDS PA_NSO signals non-extended day supply plus new-start PA requirement for the entry.
    Provider actionObtain PA when PA_NSO or NDS PA_NSO is listed to avoid denial at point of sale.
    PA_NSO definition
    PA_NSO definition (reiterated)PA_NSO indicates a prior authorization restriction for new starts; member's first fill requires PA.
    Implication for ongoing therapyPA_NSO may not apply to continuing members unless otherwise specified.
    Documentation requiredSubmit clinical justification per plan PA process when PA_NSO is flagged.
    QL / NDS distinction
    QL vs NDS distinctionQL indicates a quantity limit (e.g., EA/30 Days); NDS indicates numeric dose supply (mL) limits per period for injectable formulations.
    ExamplesQL=30 EA/30 Days; NDS QL=.75 ML/28 Days for certain injectables.
    Apply as shown per line itemFollow the exact QL or NDS value listed for that strength/formulation to determine allowable dispensing.
    QL definition (reiteration)
    QL notation reiterationExample: QL=30 EA/30 Days means 30 each per 30 days (standard one-month quantity limit).
    Use in claimsClaims must reflect days' supply and units consistent with the QL to avoid overrides.
    Multiple QL periodsSome entries use 28-day or 365-day periods; follow the period shown in the Requirements/Limits field.
    NDS PA definition (reiterated)
    NDS PA (non-standard dispensing + PA)NDS PA indicates both non-extended day supply restrictions and prior authorization are required for the product.
    ExamplesCRESEMBA and other specialty antifungals listed with NDS PA.
    Provider stepsObtain PA and adhere to NDS dispensing limits when NDS PA is present.
    PA / QL (summary)
    PA meaning in tablePA indicates prior authorization is required before the plan will cover the drug.
    QL meaning in tableQL indicates the maximum quantity allowed per the specified period (e.g., EA/30 Days).
    Combined flagsEntries may show PA and QL together (e.g., PA QL=2 ML/28 Days for REPATHA).
    QL unit examples
    QL example with GM/EA unitsQL can be in grams, e.g., QL=25.80 GM/30 Days (ATROVENT), or units, e.g., QL=30 EA/30 Days.
    Interpretation guidanceRead the Requirements/Limits field exactly to determine unit and period for the QL.
    Claims implicationDispense per the QL values to avoid claim denials or manual review.
    PA / NDS PA / PA_NSO (summary)
    PA_NSO / NDS PA / PA flags summaryPA_NSO = prior auth for new starts; NDS PA = non-extended day supply with PA; PA = prior authorization required.
    Where appliedUsed across specialty, injectables, and many high-cost agents in the formulary.
    ActionProviders must follow PA processes and submit required documentation when any of these flags appear.
    DRUG TIER (explanation)
    Drug tier numberingDRUG TIER = numeric tiers 1-5; Tier 5 typically denotes specialty/high-cost drugs.
    Use in benefit designTier determines cost-sharing and formulary placement; specialty drugs often assigned to Tier 5.
    Insulin designationINS flag used for insulin products with specific cost-sharing caps noted elsewhere in plan documents.

    Initial Coverage & Step Examples

    Step therapy for TRINTELLIX

    Step therapy applies as indicated for specific products (new‑start only where shown):

    TRINTELLIX step therapy: TRINTELLIX (all strengths) is marked ST_NSO and requires the plan's step therapy rules for new starts; QL=30 EA/30 Days also applies.QL=30 EA/30 Days

    ST_NSO indicates step therapy applies to new starts per formulary flags; prescriber must meet step criteria or request an exception.

    Initial therapy prior authorization

    Initial dispensing for listed agents may require prior authorization before coverage:

    PA_NSO required for initial therapy: Multiple agents (for example, NUPLAZID, VRAYLAR, various antipsychotics and other specialty agents) are flagged 'PA_NSO' indicating prior authorization is required prior to initial dispensing.

    See respective formulary line items for associated QL/NDS values that also apply.

    Category / Product groupRequirements / Limits
    ADHD / Anti-Narcolepsy / Anti-Obesity / Anorexiants (category-level)REQUIREMENTS/LIMITS: Category-level REQUIREMENTS/LIMITS entry present; explicit step sequences not shown in excerpt
    Amphetamines (examples: amphetamine/dextroamphetamine, lisdexamfetamine)REQUIREMENTS/LIMITS: Category-level entry present; individual strengths show QL where specified (see line items). No explicit step sequence listed
    AtomoxetineREQUIREMENTS/LIMITS = QL=30 EA/30 Days or QL=60 EA/30 Days depending on strength (per line items) — category-level sequencing not specified
    Product / ExampleRequirements / Limits (flag)
    Brivaracetam (tabs, oral solution)REQUIREMENTS/LIMITS = PA_NSO QL=60 EA/30 Days (tabs); PA_NSO QL=600 ML/30 Days (oral solution) — PA_NSO flag shown
    DIACOMIT (carbamazepine formulations)REQUIREMENTS/LIMITS include NDS / QL annotations for certain formulations; some anticonvulsant items show PA_NSO/NDS flags (specialty PA) — sequence not provided
    Other anticonvulsants (selected examples)REQUIREMENTS/LIMITS: Several anticonvulsant entries annotated with PA_NSO indicating prior authorization/new-start-only handling at PA review
    ProductStep therapy / Requirement
    TRINTELLIX (5 mg, 10 mg, 20 mg tabs)REQUIREMENTS/LIMITS = ST_NSO QL=30 EA/30 Days — ST_NSO (step therapy new-start only) applies
    ProductStep therapy flag
    TRINTELLIX (all listed strengths)ST_NSO indicated for TRINTELLIX products (ST_NSO QL=30 EA/30 Days) — step edits apply to new starts
    ScopeCoverage note / Prior authorization
    General step therapy sequences in excerptNo explicit step therapy sequences shown in the provided excerpt; several specialty/high-cost drugs require prior authorization (PA) or NDS PA before coverage
    Specialty / oncology entries (example)REQUIREMENTS/LIMITS frequently include NDS PA_NSO or NDS PA flags; PA is required prior to coverage though step order is not detailed in excerpt
    StepDescription
    Step 1(Placeholder) — no explicit step content shown in the excerpt; category-level flags present but sequences not detailed
    Agent / GroupNotes on PA_NSO and step edits
    VRAYLAR, REXULTI and similar antipsychoticsSome agents flagged PA_NSO (e.g., VRAYLAR, REXULTI) — PA_NSO may indicate step edits or requirements evaluated at PA review rather than an explicit prior step sequence
    Other antipsychotic class entriesREQUIREMENTS/LIMITS commonly include PA_NSO QL=30 EA/30 Days for many strengths; PA_NSO may trigger step-related review at prior authorization
    Excerpt scopeStep therapy sequences present?
    Table excerpt covering multiple classesNo explicit step therapy sequences shown in these chunks; entries display tiering and REQUIREMENTS/LIMITS flags only
    Product / ClassRequirement prior to coverage
    Hepatitis C direct-acting antivirals (e.g., MAVYRET, SOFOSBUVIR/VELPATASVIR, VOSEVI)REQUIREMENTS/LIMITS = NDS PA QL=... — NDS PA or PA required prior to coverage; specific step sequence is not detailed in excerpt
    PAXLOVID / PREVYMIS (examples)REQUIREMENTS/LIMITS include QL and NDS PA flags for specialty antivirals; prior authorization or non-standard dispensing required before coverage
    Table regionStep therapy sequencing shown?
    Cardiovascular / CNS / specialty entries in excerptNo explicit step therapy sequences are defined in these chunks; entries list drug tier plus PA and/or QL controls only
    Selected specialty entries with NDS PAWhere NDS PA or PA are shown (e.g., VERQUVO, EVRYSDI, RADICAVA), prior authorization and quantity limits govern coverage; step sequencing not provided in excerpt

    Per-Product Quantity Limits (Selected Examples)

    Simvastatin 80 mg — quantity limit
    Simvastatin 80 mg per-prescription limit30 tablets per prescription
    ContextListed as an example of a standard per-prescription quantity limit in the formulary explanatory text.
    Apply to dispensingPharmacies should limit fills to 30 tablets per prescription unless an exception is approved.

    Document Context

    This extract is a segment of the Part D formulary table listing multiple therapeutic classes (for example respiratory inhalers, anticoagulants and anticonvulsants), each drug’s strength/formulation, assigned drug tier, and, where applicable, utilization controls such as PA (prior authorization) and QL (quantity limits). The listing is a benefit-administration artifact and does not provide clinical prescribing guidance; coverage is governed by the tier and any Requirements/Limits shown on each line.